Table 5.
Hazard ratio of SARS-COV 2 infection and COVID-19-related mortality in patients with a history of first- and second-dose vaccination.
| First author | Vaccine type | Country | Type of study | Group of study | HR SARS-COV 2 infection | HR death related to the COVID-19 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Partial vaccinated | Full vaccinated | Partial vaccinated | Full vaccinated | |||||||||||||
| HR* | 95% CI | HR* | 95% CI | HR* | 95% CI | HR* | 95% CI | |||||||||
| Hall V. FFPH (34) | BNT162b2 mRNA | UK | Prospective cohort study | Healthcare workers. | 0.3 | 0.15 | 0.45 | 0.15 | 0.04 | 0.26 | - | - | - | - | - | - |
| Amadea Britton (74) | BNT162b2 mRNA | USA | Retrospective cohort | - | 0.37 | 0.21 | 0.67 | - | - | - | - | - | - | - | - | - |
| Adeel A. Butt (75) | BNT162b2 mRNA | Qatar | Prospective cohort study | - | - | - | - | - | - | - | - | - | - | 0.35 | 0.22 | 0.55 |
| Ioannis Baltas (76) | BNT162b2 mRNA | UK | Case–control study | - | - | - | - | - | - | - | 0.34 | 0.178 | 0.651 | |||
| M. G. Thompson (36) | BNT162b2 mRNA | USA | Prospective cohort study | Healthcare workers | 0.2 | 0.1 | 0.4 | 0.07 | 0.02 | 0.22 | - | - | - | - | - | - |
| Sara Y. Tartof (19) | BNT162b2 mRNA | USA | Retrospective cohort | Aged ≥12 years. | 0.42 | 0.39 | 0.46 | 0.27 | 0.26 | 0.28 | - | - | - | - | - | - |
| Madhumita Shrotri (37) | BNT162b2 mRNA | UK | Prospective cohort study | Age of ≥65 | 0.77 | 0.37 | 1.58 | - | - | - | - | - | - | - | - | - |
| Mark A. Katz (41) | BNT162b2 mRNA | Israel | Prospective cohort study | Healthcare workers | - | - | - | 0.055 | 0.018 | 0.174 | - | - | - | - | - | - |
| Jamie Lopez Bernal (77) | BNT162b2 mRNA | UK | Retrospective cohort | Aged ≥70 years | - | - | - | - | - | - | 0.56 | 0.47 | 0.68 | 0.31 | 0.14 | 0.69 |
| Ben Glampson (78) | BNT162b2 mRNA | UK | Retrospective cohort | Aged ≥16 years. | 0.42 | 0.36 | 0.5 | - | - | - | - | - | - | - | - | - |
| Carmen Cabezas (42) | BNT162b2 mRNA | Catalonia | Prospective cohort study | Healthcare workers | 0.13 | 0.11 | 0.14 | 0.13 | 0.11 | 0.16 | 0.31 | 0.26 | 0.39 | 0.03 | 0.02 | 0.04 |
| Tariq Azamgarhi (58) | BNT162b2 mRNA | UK | Prospective cohort study | Healthcare workers | 0.3 | 0.09 | 0.94 | - | - | - | - | - | - | - | - | - |
| Jamie Lopez Bernal (59) | BNT162b2 mRNA | UK | Case–control study | Adult age ≥70 years, | - | - | - | - | - | - | 0.49 | 0.38 | 0.63 | - | - | - |
| Ida Rask Moustsen-Helms (79) | BNT162b2 mRNA | Denmark | Retrospective cohort | Healthcare workers, | 0.17 | 0.04 | 0.28 | 0.9 | 0.82 | 0.95 | - | - | - | - | - | - |
| Peter Nordstrom (80) | BNT162b2 mRNA | Sweden | Prospective cohort | - | - | - | - | 0.22 | 0.21 | 0.22 | - | - | - | - | - | - |
| M.G. Thompson (36) | mRNA-1273 | USA | Prospective cohort study | Health care workers | 0.17 | 0.05 | 0.6 | 0.18 | 0.04 | 0.8 | - | - | - | - | - | - |
| Peter Nordstrom (80) | mRNA-1273 | Sweden | Prospective cohort | - | - | - | - | 0.13 | 0.12 | 0.16 | - | - | - | - | - | - |
| Saurabh Bobdey (61) | ChAdOx1 | India | Prospective cohort study | - | 0.559 | 0.327 | 0.954 | 0.114 | 0.0763 | 0.184 | - | - | - | - | - | - |
| Ioannis Baltas (76) | ChAdOx1 | UK | Case–control study | - | - | - | - | - | - | - | 0.216 | 0.067 | 0.696 | - | - | - |
| Madhumita Shrotri (37) | ChAdOx1 | UK | Prospective cohort study | Aged ≥65 years | 0.95 | 0.5 | 1.84 | - | - | - | - | - | - | - | - | - |
| Jamie Lopez Bernal (77) | ChAdOx1 | UK | Retrospective cohort | Aged ≥70 years | - | - | - | - | - | - | 0.45 | 0.34 | 0.59 | - | - | - |
| Ben Glampson (78) | ChAdOx1 | UK | Retrospective cohort | Aged ≥16 years. | 0.59 | 0.49 | 0.71 | - | - | - | - | - | - | - | - | - |
| Peter Nordstrom (80) | ChAdOx1 | Sweden | Prospective cohort | - | - | - | - | 0.5 | 0.42 | 0.59 | - | - | - | - | - | - |
| Mark G. Thompson (49) | Combination† | USA | Prospective cohort study | Healthcare workers | 0.2 | 0.1 | 0.41 | 0.1 | 0.03 | 0.32 | - | - | - | - | - | - |
| Ashley Fowlkes (50) | Combination† | USA | Prospective cohort study | Healthcare workers | 0.2 | 0.12 | 0.31 | - | - | - | - | - | - | |||
| Sarah E. Waldman (81) | Combination† | USA | Retrospective cohort | Age ≥18 year old | 0.53 | 0.4 | 0.71 | 0.22 | 0.12 | 0.42 | - | - | - | - | - | - |
| Maria Elena Flacco (64) | Combination† | Italy | Retrospective cohort | Aged ≥18 years. | 0.05 | 0.04 | 0.06 | 0.02 | 0.01 | 0.03 | 0.03 | 0.01 | 0.08 | 0.02 | 0 | 0.12 |
| Baltazar Nunes (71) | Combination† | Portugal | Prospective cohort study | Aged ≥65 years. | - | - | - | - | - | - | 0.23 | 0.12 | 0.44 | 0.04 | 0.02 | 0.08 |
*
Hazard Ratio adjusted in each study.
†
BNT162b2 mRNA and mRNA-1273 and ChAdOx1.